{
  "ticker": "ACW",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973227",
  "id": "02973227",
  "pages": 4,
  "price_sensitive": false,
  "date": "20250728",
  "time": "0946",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250728/pdf/06m6g42kwtpm1d.pdf",
  "summary": "- **Scientific Presentation**: Poster at AAIC 2025 highlights **Xanamem\u00ae** (11\u03b2-HSD1 inhibitor) showing **clinically significant improvements** in **Major Depressive Disorder (MDD)** via cortisol reduction in the brain.  \n- **Clinical Validation**: Supports **10mg daily dose** for ongoing **Phase 2b/3 XanaMIA trial** in **Alzheimer\u2019s Disease** (interim data expected Jan 2026, final results Q4 2026).  \n- **Safety Profile**: Well-tolerated in trials (400+ participants), with no major safety concerns reported.  \n\n**No material trading/capital markets information identified** (operational update only).",
  "usage": {
    "prompt_tokens": 4048,
    "completion_tokens": 147,
    "total_tokens": 4195,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-27T23:54:35.128184"
}